Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...

A population estimate is a measure of the current or historical population at a particular point in time. These are the key highlights for the fourth quarter of 2024: Alberta maintained its position ...

Cathie Wood’s ARK ETFs have disclosed their daily trades for Friday, March 14th, 2025, with significant transactions across a ...

Daiwa Securities Group Inc. grew its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 80.6% during the 4th quarter, according to the company in its most recent 13F ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Kaufman Center for Heart Failure Treatment and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, OH (S.V., W.H.W.T.). Kaufman Center for Heart Failure Treatment and Recovery, Heart ...

The recent HELIOS-B trial data for Amvuttra (vutrisiran) in ATTR cardiomyopathy (ATTR-CM) has significantly bolstered Alnylam’s prospects. The study demonstrated a statistically significant effect on ...